Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-Tolerated Safety Profile

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing